Final FDA Approval

Zydus Lifesciences Limited (NSE: ZYDUSLIFE) announced the final FDA approval for its ascorbic acid injection USP on August 21, 2026, under ANDA 220873. The approved strengths are 25,000mg/50mL and 5,000mg/10mL, both with a concentration of 500mg/mL. The FDA designated the product as a Competitive Generic Therapy (CGT), granting 180-day exclusivity from the first commercial sale if criteria are met. The key point is the regulatory entry of a generic injectable in the U.S., not merely an update to existing data.

Drug and Clinical Position

This product is a generic referencing McGuff Pharmaceuticals' branded product Ascor, with the generic name ascorbic acid. It delivers vitamin C intravenously. Ascorbic acid functions as a reducing cofactor for prolyl and lysyl hydroxylases, playing a role in collagen synthesis and tissue maintenance, rather than acting as a single-receptor blocking drug. The approved indication is for the treatment of scurvy in patients aged five months and older who cannot tolerate, are insufficient for, or have contraindications to oral administration, for up to one week. The development stage is not clinical trials but FDA-approved and marketed. High-dose intravenous vitamin C for oncology or sepsis is not included in this approval.

Competition and Regulatory History

The reference drug Ascor was approved by the FDA on October 2, 2017, under NDA 209112 by McGuff Pharmaceuticals, without a separate advisory committee (AdComm) vote. Fresenius Kabi USA received the first generic approval for Ascor on August 7, 2025, under ANDA 217131, and has already entered as a key competitor. Therefore, Zydus' CGT exclusivity does not mean total exclusivity for all ascorbic acid injections, but is tied to the commercial launch timing of the specific CGT product and strength approved by the FDA. From a standard-of-care perspective, oral vitamin C is preferred, and injectables target a limited patient population where oral therapy is not feasible.

Market Potential and Business Implications

According to Zydus, IQVIA MAT data as of June 2026 indicates that the annual U.S. sales of Ascor are approximately USD 11.6 million. While not a large blockbuster market, the entry barriers include orphan indications, aseptic injectable manufacturing, and hospital procurement, making supply stability and manufacturing quality as important as pricing. The product will be produced at Zydus' FDA-approved injectable facility in Jarod, Gujarat, India, and marketed in the U.S. by Zydus Pharmaceuticals USA. The addition of the 10mL strength and temporary CGT exclusivity is favorable for hospital inventory efficiency and early market share capture, but the existing supply chain of Fresenius Kabi and the original Ascor sets an upper limit on profitability.